Last Updated : April 20, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort descending |
---|---|---|---|---|---|---|
Inlyta (RFA) | Axitinib | Metastatic Renal Cell Carcinoma | N/A | Complete | ||
Talzenna | talazoparib | Metastatic castration-resistant prostate cancer (mCRPC) | Suspended | |||
Nurtec ODT | rimegepant | Migraine, prevention | Withdrawn | |||
Eylea HD | aflibercept 8mg/0.07mL | macular degeneration, age related | Active | |||
Eylea HD | aflibercept 8mg/0.07mL | diabetic macular edema | Active | |||
Tecvayli | teclistamab | Relapsed or refractory multiple myeloma | Active | |||
Paxlovid | nirmatrelvir/ritonavir | Mild-to-moderate COVID-19, treatment | Active | |||
Isturisa | osilodrostat | Endogenous Cushing’s syndrome | Suspended | |||
Remsima | infliximab | Crohn’s disease | Active | |||
Hemgenix | etranacogene dezaparvovec | Hemophilia B | Active |